Letonia - letonă - Zāļu valsts aģentūra

ingen pharma, sia, latvia - klaritromicīns - apvalkotā tablete - 250 mg

Letonia - letonă - Zāļu valsts aģentūra

ingen pharma, sia, latvia - klaritromicīns - apvalkotā tablete - 500 mg

Uniunea Europeană - letonă - EMA (European Medicines Agency)

mediwound germany gmbh - proteolytic enzymes enriched in bromelain - debridement - preparāti brūču un čūlas ārstēšanai - nexobrid ir indicēts, lai pieaugušajiem ar dziļu daļēju un pilnīgu biezu termisko apdegumu noņemtu eschar.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

astrazeneca ab - olaparibs - olnīcu jaunveidojumi - antineoplastiski līdzekļi - olnīcu cancerlynparza ir norādīts kā monotherapy par:apkope ārstēšanai pieaugušiem pacientiem ar progresējošu (figo posmos, iii un iv) brca1/2-mutācijas (dzimumšūnas līnijas un/vai somatisko) augstas kvalitātes epitēlija olnīcu, olvados, vai primāro peritoneālās vēzi, kas ir atbildes reakcija (pilnīgu vai daļēju) pēc pirmās līnijas platīna ķīmijterapiju. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 un 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. pacientiem ir jābūt iepriekš apstrādāts ar anthracycline un taxane gadā (neo)palīgvielu vai metastātiska iestatījumu, ja vien pacientiem nebija piemēroti šiem apstrādes veidiem (skatīt 5. iedaļu. pacientiem ar hormonu receptoru (ap)-pozitīvs krūts vēzis ir arī ir bijuši par to, vai pēc iepriekšējas endokrīnās terapijas, vai būt nepiemērota par endokrīnās terapijas. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

Letonia - letonă - Zāļu valsts aģentūra

unifarma, sia, latvija - lansoprazolum, tinidazolum, clarithromycinum - kapsula + tablete

Uniunea Europeană - letonă - EMA (European Medicines Agency)

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

roche registration gmbh - vismodegib - karcinoma, bazālā šūna - antineoplastiski līdzekļi - erivedge ir norādīts ārstēšanai pieaugušiem pacientiem ar:- simptomātiska metastātisku bazālo šūnu karcinomu - lokāli papildu bazālo šūnu karcinomu nepiemērotu operācijas vai radioterapijas.

Letonia - letonă - Zāļu valsts aģentūra

viatris sia, latvia - klaritromicīns - apvalkotā tablete - 500 mg

Letonia - letonă - Zāļu valsts aģentūra

teva pharma b.v., netherlands - ciklosporīns - mīkstās kapsulas - 10 mg

Letonia - letonă - Zāļu valsts aģentūra

teva pharma b.v., netherlands - ciklosporīns - kapsula, mīkstā - 25 mg